With the booming development of CAR-T cell therapy, new CAR-T concepts and technologies emerge monthly. I’ve attempted to compile some of these here to encourage our patients—countless scientists and medical professionals are fighting alongside us in the fight against cancer, constantly achieving new victories. A recent clinical trial of CAR-T therapy for colorectal cancer demonstrated initial anti-tumor efficacy in patients with advanced colorectal cancer (mCRC). Conducted by the First Hospital of Jilin University, the trial evaluated the safety and efficacy of a CAR-T cell product called GCC19CART. GCC19CART is a CAR-T cell combination targeting guanylate cyclase C (GCC) and CD19. GCC is a protein expressed in approximately 70-80% of colorectal cancer metastases, while in normal tissues it is only expressed on the inner surface of the intestine, making it highly targeted. The trial enrolled 15 patients with mCRC who had undergone extensive chemotherapy and received GCC19CART. Trial results showed that the therapy produced objective responses in 40% of patients, with some experiencing significant tumor shrinkage. The overall safety and tolerability of GCC19 CART was good. Side effects during treatment included cytokine release syndrome (CRS) and diarrhea. Most patients experienced mild to moderate CRS, which was primarily managed with steroids and immunosuppressive drugs, while the diarrhea was mostly manageable and reversible. A highlight of this study is its innovative CoupledCAR platform, which enhances the activity of GCC-targeting CAR-T cells through the expansion of CD19 CAR-T cells. This mechanism has demonstrated its clinical potential in the treatment of solid tumors for the first time, indicating that CAR-T therapy has promise not only in hematologic malignancies but also in other solid tumors such as colorectal cancer. Non-relapse mortality after CAR-T therapy: Non-relapse mortality (NRM) refers to deaths after CAR-T therapy due to treatment side effects or complications, rather than tumor relapse. A systematic review and meta-analysis investigated NRM in patients with different hematologic malignancies after CAR-T therapy. The study found significant variation in NRM across different diseases. For example, NRM rates are as high as 10.6% for patients with mantle cell lymphoma, 8.0% for multiple myeloma, 6.1% for large B-cell lymphoma, and 5.7% for indolent lymphoma. These differences may be related to factors such as the patient’s underlying condition, the choice of CAR-T product, and the number of lines of treatment. Infection is the most common cause of non-relapse mortality after CAR-T therapy, accounting for 50.9% of all non-relapse deaths. Studies have also found that COVID-19 plays a significant role in infection-related deaths, especially during the global pandemic. In addition, bacterial and fungal infections significantly increase the risk of death. Cardiovascular and respiratory complications are the second leading cause of death, accounting for 7.3%. Therefore, infection control is particularly critical during CAR-T therapy. While CAR-T therapy-specific side effects do exist, such as cytokine release syndrome (CRS) and intracranial toxicity syndrome (ICANS), they account for a relatively small proportion of non-relapse deaths, accounting for only 11.5% of total deaths. Understanding and managing CAR-T-related toxicities: With the widespread clinical application of CAR-T therapy, physicians have gradually identified some previously unidentified side effects.Palbociclib Cell Cycle/DNA Damage For example, some patients developed movement disorders, immune effector cell-associated hematotoxicity (ICAHT), and immune effector cell-associated hemophagocytic syndrome (IEC-HS) after treatment. The identification and management of these toxic reactions are critical to ensuring the safety of treatment. In addition, because CAR-T cell therapy may lead to persistent B cell loss and decreased immunoglobulins (hypogammaglobulinemia), patients are also at higher risk of infection. For this reason, doctors have begun to use more diverse immunosuppressive and supportive treatment options to manage these toxic reactions. Although there are a variety of treatment options, there is currently no universally applicable standard algorithm to deal with these side effects. With the continuous development of CAR-T cell productsCAR-T cell therapies targeting novel targets are being developed. However, this also presents a new challenge: when the targeted antigen is expressed in non-malignant tissues, it may cause damage to these normal tissues. Therefore, designing CAR-T cell products with reduced toxicity and continuously optimizing toxicity management strategies are crucial. Future success in this field will depend on prospective assessment and improvement of CAR-T therapy toxicity. Through continuous research and improvement, we hope to improve therapeutic efficacy while minimizing treatment risks and side effects. While CAR-T therapy holds great promise, it also requires careful management to ensure optimal patient outcomes and safety. Mechanisms of CAR-T cell expansion in solid tumors: A recent clinical trial of GD2 CAR-T cells in patients with solid tumors demonstrated that the characteristics of different immune cells are closely associated with CAR-T cell expansion.Temozolomide Cell Cycle/DNA Damage In this study, scientists conducted a detailed immune profile of patients with osteosarcoma and neuroblastoma who received GD2 CAR-T cells.PMID:35105808 They found that patients with a higher number of CXCR3-positive monocytes in their blood before treatment had significantly more CAR-T cell expansion in vivo. These CXCR3-positive monocytes are an activated monocyte subset capable of releasing signals during immune responses, promoting the proliferation and function of CAR-T cells. Conversely, patients with a high proportion of CXCR3-negative monocytes in their blood experience poor CAR-T cell expansion, as these monocytes may play a suppressive role in the immune environment. Furthermore, studies have found that patients with a high pre-treatment population of naive T cells generally experience better CAR-T cell expansion during treatment. These naive T cells, having not undergone multiple immune activations, possess high activity and differentiation potential, contributing to a stronger anti-tumor response during CAR-T therapy. The study further revealed that after CAR-T therapy, as the number of CAR-T cells gradually decreased, the proportion of CXCR3-negative classical monocytes increased across all patients. This suggests that these cells may inhibit the persistence and expansion of CAR-T cells, leading to reduced therapeutic efficacy. Furthermore, if the CAR-T product itself contains a high number of exhausted T cells, their expansion and anti-tumor efficacy will be significantly limited after infusion. Therefore, the researchers pointed out that during the production process of CAR-T products, it is necessary to focus on screening and reducing these exhausted T cells to ensure that the final CAR-T cells can achieve better expansion and persistence in the patient’s body. References: 1. Chen N, Pu C, Zhao L, et al. Chimeric Antigen Receptor T Cells Targeting CD19 and GCC in Metastatic Colorectal Cancer: A Nonrandomized Clinical Trial[J]. JAMA oncology. 2. Cordas dos Santos DM, Tix T, Shouval R, et al. A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy[J]. Nature medicine, 2024, 30(9): 2667-2678. 3. Brudno JN, Kochenderfer J N. Current understanding and management of CAR T cell-associated toxicities[J]. Nature Reviews Clinical Oncology, 2024: 1-21. 4. Kaczanowska et al., Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy, Cancer Cell (2023), /10.1016/j.ccell.2023.11.011MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com